ABOUT US
CHIGENOVO Co., Ltd.
CHIGENOVO Co., Ltd. is a national high-tech enterprise focusing on gene therapy drug development and genetic diagnosis for inherited eye diseases. We are committed to providing "one-stop" solutions for precision therapy and diagnosis for patients with genetic eye diseases.
Learn moreFocusing on ophthalmology, to provide patients with the whole process of diagnosis and treatment "one-stop" solutions.
Gene replacement therapy and gene editing therapy complement each other and work synergistically.
Drug R&D and evaluation, AAV R&D and production, and drug clinical trial of three state-of-the-art platforms.
ZVS101e and ZVS203e have orphan drug designations granted by FDA, and multiple pipelines are under research.
Company
Since founded in 2016, CHIGENOVO has been committed to providing one-stop solutions for the diagnosis and treatment of inherited eye diseases.
Gene therapy drug development
Starting from IRDs, dedicated to the treatment of various eye diseases
Precision diagnostic process for genetic eye diseases
Focusing on precision diagnosis of eye diseases and public vision health
Ophthalmic genetic diseases have significant clinical and genetic heterogeneity. In order to achieve accurate diagnosis, first, detailed medical history and family history are required. Second, clinical examination and necessary functional and imaging examinations (visual electrophysiology, optical coherence tomography, fundus photography and fundus autofluorescence, etc.) are performed. Third, due to the variety of pathogenic gene mutations, genetic testing is required. On the premise of clarifying the relationship between genes and diseases, combined with the clinical phenotype of the disease, the genetic mode of the disease and the degree of pathogenicity of the variation, the pathogenic or likely pathogenic variation that can clearly explain the phenotype of patient is identified. Finally, the candidate mutation is verified by familial co-separation analysis. After the above clinical-laboratory-clinical diagnosis process, accurate diagnosis can be completed, which is the premise of further accurate treatment and prevention.
Learn more
Gene Diagnosis of Ophthalmic Diseases
News Center
Real-time updates CHIGENOVO and industry trends
undefined
CHIGENOVO Co., Ltd. is an ophthalmic gene therapy company, a national high-tech enterprise focusing on genetic diagnosis of genetic eye diseases and the development of gene therapy drugs. It is committed to providing "one-stop" services for patients with genetic eye diseases.
HUATAO GROUP
Contact us
Telephone:400-6006223 010-82071936
Website:en.chinagene.cc
Address: Floor 4, Area D, Building 1, No.27 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing
WeChat subscription account